JAMA Internal Medicine
JAMA Internal Medicine(英文缩写 JAMA INTERN MED),ISSN 2168-6106,eISSN 2168-6114 是一本学术期刊。本页汇总该期刊的最新影响因子、分区信息以及最新收录于 PubMed 的文献,帮助您快速了解期刊全貌。
发文量统计区间：2025-09-01 至 2026-08-31，按本站收录文献的发表日期统计。
期刊介绍
历年影响因子趋势
| JCR 数据年份 | 影响因子 | JCR 分区 |
|---|---|---|
| 2021 | 44.424 | Q1 |
| 2022 | 39.000 | Q1 |
| 2023 | 22.500 | Q1 |
| 2024 | 23.300 | Q1 |
| 2025 | 26.300 | Q1 |
JAMA Internal Medicine 最新收录文献
-
2. Antidiscrimination Laws and Kidney Transplant for Patients With Developmental Disabilities.
PMID:日期:2026-09-21该文献暂无摘要。
-
4. Steatotic Liver Disease Risk Scores to Predict Cirrhosis and Hepatocellular Carcinoma.
PMID:日期:2026-09-21Most individuals with steatotic liver disease (SLD) do not develop advanced liver disease. Multiple risk scores for SLD-associated cirrhosis and hepatocellular carcinoma (HCC) have been proposed, but their utility to inform decisions about surveillance for advanced liver disease is unknown. To compare the clinical utility of SLD risk scores for predicting cirrhosis and hepatocellular carcinoma in patients with noncirrhotic steatotic liver disease. This cohort study used data from the national US Veterans Affairs health system of adults with imaging-confirmed SLD without viral hepatitis or primary liver disease from 2008 and 2020. Nine clinical risk scores were calculated at the time of the first imaging results that demonstrated hepatic steatosis. Individuals were followed up until cirrhosis, HCC, death, or 6 months after last follow-up visit. Data were analyzed between November 1, 2025, and May 11, 2026. Nine risk scores evaluated for prediction of cirrhosis or HCC within 10 years were: (1) ALBI, albumin-bilirubin; (2) aMAP, age-male-albumin-bilirubin-platelet; (3) APRI, the aspartate aminotransferase-to-platelet ratio; (4) BARD, body mass index, age, alanine aminotransferase-to-aspartate aminotransferase ratio, and diabetes; (5) FIB-4, fibrosis-4 index; (6) NFS, nonalcoholic fatty liver disease fibrosis; (7) SAFE, steatosis-associated fibrosis estimator; and 2 additional scores. First diagnosis of cirrhosis and first diagnosis of HCC identified using VA and Medicare diagnosis codes and data from the VA Cancer Registry. Cox proportional hazards models were used to calculate time-dependent 10-year probabilities of each outcome predicted by 9 risk scores. Decision curves were generated for each outcome by calculating the net benefit, a weighted measure of true and false positives over a prespecified range of risk thresholds at which a clinician may reasonably recommend intervention. Nine risk scales were used to quantify the risk of cirrhosis or HCC within 10 years. The analysis included 853 131 patients (median [IQR] age, 61 [51-68] years; 62 168 females [7.3%] and 790 965 males [92.7%]) whose median (IQR) BMI was 31.3 (27.6-35.5) and 275 898 (32.3%) had diabetes; of these, 33 794 (3.96%) developed cirrhosis and 2978 (0.35%) developed HCC within 10 years. The FIB-4, APRI, and SAFE scores demonstrated the greatest discrimination of cirrhosis risk, while the SAFE, Tate, and FIB-4 scores demonstrated the greatest discrimination of HCC risk. The SAFE score demonstrated the greatest net benefit predicting cirrhosis. A score of 29.5 corresponded to a 10-year cirrhosis risk of 2.5% and yielded a net benefit of 0.019, or 1.9 additional individuals who develop cirrhosis per 100 individuals classified as at-risk patients. At a 0.25% 10-year risk of HCC, the SAFE score had a net benefit of 0.0016 (1.6 additional true positives per 1000 individuals). The findings of this cohort study show that the SAFE score may inform decisions to repeat screening for cirrhosis in patients with SLD. Clinical risk scores for HCC demonstrated minimal utility to inform HCC screening decisions for patients with noncirrhotic SLD.
-
6. Effective Palliative Care for Hospice Transitions.
PMID:日期:2026-09-14Variation in hospice use for patients with cancer exists between palliative care programs, but factors underlying this heterogeneity are unknown. To identify hospital and palliative care program factors that may impact the ability of palliative care teams to affect hospice use in cancer. This multicenter qualitative study included 6 palliative care programs in the United States. Using a cohort of patients with metastatic cancer who received specialist palliative care, a positive-negative deviance approach was used to select 3 programs with high and 3 programs with low performance on hospice use. In-depth site visits were conducted and included semistructured interviews with palliative care and oncology clinicians and patients as well as in-person observation. Interviews were conducted from February 2025 to January 2026. Site visits were conducted from May 2025 to January 2026. Program-specific practices and their potential effect on hospice use for patients with cancer. A total of 93 interviews and 424 hours of in-person observation were conducted across 6 palliative care programs in the Midwest, Upper South, and Deep South regions of the United States. Interview participants had a median (IQR) age of 43 (37-47) years; 68 (73.1%) were female; clinicians had a median (IQR) of 11 (5-16) years of experience. There were notable differences in the relationships between palliative care and oncology teams between high- and low-performing programs. At high-performing programs, the relationship was characterized by mutual trust and respect, warmth and familiarity, and empathy for each other, whereas at low-performing programs, the relationship was characterized by a lack of trust and familiarity and negative regard for each other. Factors observed in programs with positive relationships included intentionality in relationship building, physical presence and proximity between teams, use of real-time communication, and the palliative care team having a service-oriented mentality and a reputation for reliable service. At high-performing programs, observable differences in care included collaborative care delivery, increased access and timeliness of palliative care, and earlier introduction of hospice by oncology clinicians. In this multicenter qualitative study, differences in the relationship between palliative care and oncology teams were identified that may mechanistically affect end-of-life patient outcomes. These findings are important to ensure the delivery of high-quality care for all patients with cancer.
-
8. Universal Opt-Out Hepatitis C Virus Testing and Treatment on Entry in California State Prisons.
PMID:日期:2026-09-14该文献暂无摘要。